Search

everythinglearnresearchcommunity

for

Search:↓

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

CDKN2AIP gene is less active in nevus sebaceous, affecting related RNA networks.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

PKC ε increases hair follicle stem cell turnover and may raise skin cancer risk.

The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.

High ornithine decarboxylase levels may lead to hair loss and cancer by increasing CK2 activity in the nucleus.

CENPV, a new partner of CYLD, helps regulate ciliary acetylated tubulin and is overexpressed in certain skin tumors.

MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.

CS12192 effectively treats alopecia areata with better safety than current options.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

PPARγ signaling modulation can protect hair follicle stem cells from chemotherapy-induced damage.

Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

EGFR inhibitors can cause skin issues, but managing them is important for treatment success.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Compounds from Alpinia zerumbet may help with hair regrowth and cancer treatment by targeting PAK1.

A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.